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ABSTRACT 
Objective: The management of inflammatory bowel disease (IBD) patients on complex medications such as biologic disease-modifying anti-
rheumatic drugs (DMARD) requires close supervision. At East Sussex NHS Healthcare Trust (ESHT), the multi-disciplinary team (MDT) already 
looking after these patients could benefit from the additional knowledge and support from a specialist pharmacist (SP). 
Methods: To assess if the MDT could benefit from an SP, all IBD patients on the DMARD adalimumab were identified. The patient records were 
screened for patient demographic data, clinical assessment and investigations, treatment, and follow-up clinics. 
Results: 162 patients at ESHT were identified as being on adalimumab treatment for either Crohn’s Disease (77%) or Ulcerative Colitis (23%). 
Disease activity scores, a clinical measure of IBD severity, were infrequently recorded (1%) on patient letters. Evidence of a biologic screen, a series 
of investigations to ensure safety in a biologic treatment, was only evident in one-third of patients. Clinic review of patients recently started on 
adalimumab and annual review of stable patients occurred 43% and 26% respectively. 
Conclusion: The results indicate that there is a need for an additional member to support the IBD MDT in managing this cohort of patients. An SP is 
uniquely positioned to fill this gap. They have extensive knowledge in drug indication, therapeutic drug monitoring, and side-effect profiles. Similar 
studies have been identified that support SP in this role. 
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INTRODUCTION 
Specialist pharmacists (SP) have increasingly been playing a role in 
the treatment of conditions that require complex pharmacological 
management [1]. The role of the pharmacist has been expanding 
from conventional duties to becoming more independent, allowing 
them to prescribe for patients within a defined scope of practice [2–
5]. These additional duties to monitor patients and prescribe for 
them can reduce the workload on other healthcare professionals. 
This is reflected in the study by Walter et al., which found that 
employing specialist clinical cancer pharmacists reduced clinic visits 
and reduced workload on the doctor [3]. The role of the SP in 
managing inflammatory bowel disease (IBD) has not been widely 
assessed to date. The management of IBD could lend itself well to the 
role of an SP considering the complex IBD drug management, 
comprehensive monitoring for side effects, and following up on 
therapeutic drug monitoring (TDM). Additionally, patient education 
is essential towards long-term compliance and management. IBD is a 
condition frequently seen in gastroenterology, affecting more than 
400,000 people in the UK alone [6]. It can be divided into two 
distinct clinical conditions-Crohn’s Disease (CD) and Ulcerative 
Colitis (UC) [7]. CD is a chronic inflammatory condition having 
patchy regions of inflammation. These can be found throughout the 
alimentary tract but are most commonly found in the ileocecal 
region [7]. The inflammation is transmural, thereby affecting all the 
layers. In UC, the inflammation is usually contained to the rectum 
and proximal colon [7]. The inflammation and ulceration are 
contained in the colonic mucosa. The medical treatment of both 
conditions revolves around the use of anti-inflammatories and 
immunosuppressants (e. g. steroids), and disease-modifying 
antirheumatic drugs (DMARD)[8]. First-line medications consist of 
corticosteroids, aminosalicylates, and azathioprine whilst anti-tissue 
necrosis factor-alpha (TNF-a) agents such as adalimumab or 
infliximab are reserved for more moderate-severe cases [9, 10]. 
These medications may require careful and regular monitoring by 
specialist teams in secondary care. Patients have to be assessed to 
ensure therapeutic drug levels, drug metabolism, immunogenicity, 
and side effects [11]. One of the anti-TNF-a inhibitors prescribed for 
patients with IBD is the monoclonal antibody adalimumab. Its 
mechanism of action is by inhibiting TNF-a by binding to soluble 
TNF-a and preventing its interaction with cellular TNF-a receptors 
[12]. Adalimumab is a biologic DMARD (bDMARD) and is indicated 
in adult patients with moderate to severe CD or UC who have had an 
inadequate response to conventional therapy. The inadequate 
response is often clinically assessed, with bowel motions per day 
being an important component [11]. The IBD patients on 
adalimumab requiring highly individualized, frequent, and complex 
care calls for and provides an opportunity for SPs to assist the 
healthcare team in monitoring and treating these patients. This 
paper aims to establish the current management of patients on 
adalimumab and to assess the need for an SP in managing patients 
on adalimumab at East Sussex Healthcare NHS Trust (ESHT). 
MATERIALS AND METHODS 
Blueteq® is an electronic platform used to monitor compliance with 
national guidelines[13]. At ESHT the Blueteq® database was used to 
identify all patients on active adalimumab treatment in November 
2018. This was verified using the pharmacy dispensing record 
system. Patients were excluded if they could not be verified using 
the pharmacy dispensing record system. Once all patients on active 
adalimumab had been established, data was collected by using the 
pharmacy dispensing system and the clinical database, which 
provides access to patient details, laboratory results, and clinical 
letters. All patients were then reviewed by a virtual multi-
disciplinary team (MDT) meeting, which included an SP and a 
Consultant Gastroenterologist. The patient’s management was 
reviewed and the potential for further assessment or change in 
management was evaluated. These outcomes were all recorded in an 
excel spreadsheet. Any actions or follow-ups required for existing 
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patients that were reviewed as part of this research were fed back to 
the IBD specialist nurses. 
Patient documents were screened for baseline patient 
demographics, clinical assessments and investigations, treatment, 
and follow-up. Clinical assessment of patients was quantified 
through clinical scoring systems, using either the Harvey Bradshaw 
Index (HBI) for CD or the Truelove and Witts score for UC [14, 15]. 
Basic investigations included fecal calprotectin and patient weight. A 
low BMI secondary to malnutrition is common in patients with 
undiagnosed IBD or those who are relapsing. Fecal calprotectin is an 
established marker to distinguish between IBD and irritable bowel 
syndrome [11, 16]. 
RESULTS 
Patient demographics and characteristics 
The study identified 162 patients at ESHT through the Blueteq® 
system, which were labelled as receiving adalimumab (table 1). The 
average age of the patient cohort was 45, with a standard deviation 
of 17 y. The majority of patients on adalimumab were being treated 
for CD (77%), whilst the rest were treated for UC (23%). 
 
Table 1: Patient demographics and characteristics 
Parameter  
Number of Patients 162 
Age (years) 46±17 
Male/Female Ratio 69/93 
Crohn’s Disease 125 
Ulcerative Colitis 37 
 
Initial assessment and investigations 
Initial assessment and investigations are listed in table 2. Disease 
activity was infrequently recorded in the patient letter (1%). A 
review of the Blueteq® system showed that disease activity scores 
were documented in 77% of the cases. This can largely be explained 
as it is a mandatory requirement most of the time on the Blueteq® 
system. A minority of patients (21%) were assessed using fecal 
calprotectin. The majority of patients (76%) were investigated with 
further interventions. Of those documented (table 3) the most 
common interventions were colonoscopy, magnetic resonance 
imaging scans, and sigmoidoscopies. 
Table 2: Initial assessment and investigations 
Parameters Yes No Not available 
Disease activity scores on patient letter 2 (1%) 158 (98%) 1 (2%) 
Disease activity scores on Blueteq® 124 (77%) 16 (10%) 22 (13%) 
Interventions carried out 123 (76%) 37 (23%) 2 (1%) 
Pre-Biologic screen 54 (33%) 107 (66%) 1 (1%) 
Fecal Calprotectin 34 (21%) 127 (78%) 1 (1%) 
Weight documented 9 (5%) 152 (94%) 1 (1%) 
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Table 3: Illustrates the number of investigations performed to assess 
the disease severity of patients with IBD before starting adalimumab 
treatment. Data represents the total amount; patients could have 
multiple and repeat investigations. 
 
Pre-biologic screening 
Before starting a patient on a biologic such as adalimumab, the British 
Society of Gastroenterology (BSG) guidance recommends carrying out 
a pre-biologic screen [11]. This is to ensure that there are no absolute 
contraindications to commencing treatment. At ESHT a pre-biologic 
screen consists of a standard blood test, a viral screen, T-spot test, a 
chest x-ray, and a pregnancy test if relevant. Clinic letters only 
recorded that a pre-biologic screen was conducted one-third of the 
time (33%). Monitoring weight trends is important in patients with 
IBD; however, it was rarely (5%) documented in clinic letters. 
Treatment and management of patients with IBD on adalimumab 
A total of 162 patients were identified by Blueteq® as being on 
active adalimumab treatment, however, 25 patients (15%) were not 
actively receiving the medication. Further analysis showed that 
some patients had developed new contraindications to the 
medications whilst others did not engage with the healthcare 
system. A large proportion (72%) of clinic records did not indicate 
that patients were involved or given a choice about starting biologic 
treatment (table 4). The Hackett report emphasizes that patients 
should be involved in treatment decisions and routes of 
administration [17]. It found this to be beneficial for patient 
compliance and treatment. The treatment regime for CD and UC may 
be escalated to a more frequent dosing regimen (once every 2 w to 
weekly). Data collected shows that 23% of CD patients and 35% of 
UC patients had their treatment escalated (table 4). After a decision 
to escalate treatment frequency has been taken, it is best practice to 
assess if the patient has developed any antibodies to the treatment 
and to elicit drug trough levels [11]. This was identified on clinic 
records as only occurring 21% of the time (table 4). 
Biologic treatment with adalimumab should be discontinued once 
a prolonged corticosteroid-free remission has been observed [11]. 
In total, only 4% of cases showed clear documentation about 
duration and treatment cessation. A comparison between the 
treatment dose of adalimumab the patient actually receives and 
that recorded in the Blueteq® system is difficult to evaluate, as 
98% of patients in the Blueteq® do not have their dosing 
frequency recorded. The Blueteq® system does not make this a 
mandatory requirement. This contributes to the low rate (2%) of 
concurrence of the recorded dose in the Blueteq® system 
compared to clinic notes. 
 
Table 4: Treatment and management of patients with IBD on adalimumab 
Parameter Yes No Not Available 
Receiving Treatment 136 (84%) 25 (15%) 1 (1%) 
Escalation by Indication Crohn’s Disease 29 (23%) 96 (77%) 0 (0%) 
Ulcerative Colitis 13 (35%) 24 (65%) 0 (0%) 
Levels taken on treatment escalation 9 (21%) 32 (76%) 1 (2%) 
Patient involved in decision making 44 (27%) 116 (72%) 2 (1%) 
Documentation stopping treatment 6 (4%) 155 (95%) 1 (1%) 
Concurrence of Blueteq and Actual Dose 3 (2%) 0 (0%) 159 (98%) 
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Follow-up of patients on adalimumab 
The 3-month review after treatment started is an important 
timeframe as the clinician can assess the effectiveness against the 
side effects. Generally accepted practice along with BSG guidance is 
for a review of IBD patients on biologics within a month after the 
loading dose has been completed, which in this scenario equates to a 
3-month review [11]. Any review occurring 28 d before and after 3 
mo of starting treatment was included. The review showed that only 
43% of patients were reviewed within this timeframe (table 5). A 
regular review should occur yearly after starting adalimumab 
treatment [9, 10]. A large proportion of patients did not have any 
data available on yearly follow-up (28%). Almost half of the patients 
(46%) did not have any evidence or did not have the annual review 
within the required timeframe. Only 26% of patients were seen at a 
one-year follow-up with a 28-day leeway on either side. Patients 
were followed up in the clinic more frequently than required by 
NICE guidelines. The records showed that 73% of patients had an 
additional clinic scheduled. Following data collection and MDT 
review 77% of patients were identified as needing a review due to 
no recent review in a clinic, missing information, requiring follow-up 
investigations, or treatment alterations. 
 
Table 5: Follow-up of patients on adalimumab 
Parameter Yes No Not Available 
3-Month Review 69 (43%) 81 (50%) 12 (7%) 
Annual Review 42 (26%) 74 (46%) 46 (28%) 
Additional clinic 119 (73%) 39 (24%) 4 (2%) 
Patient review after MDT 125 (77%) 35 (22%) 2 (1%) 
 
DISCUSSION 
The results of this study highlight that important parameters which 
strongly influence patient care have a low rate of documentation. 
This is evidenced by 1% of clinic notes recording disease activity 
scores or 4% of clinic letters having treatment cessation 
information. Having more reliable records will allow the healthcare 
team to establish a trend, improve continuity of care and facilitate 
more accurate audits. Disease activity scores in IBD can be used as a 
tool to identify patients with more aggressive disease that require 
escalation of treatment. The data collected found only 1% of patient 
letters to contain a disease activity scores. A review of Blueteq®, a 
system primarily only accessible to pharmacists, indicates 77% of 
patients on adalimumab have disease activity scores logged. It would 
be of benefit for these disease activity scores to be more accessible 
to the wider healthcare team. This would allow for improved 
continuity of care and establishing a disease trend. Similarly, the 
weight of a patient is also rarely documented (5%). This again would 
provide benefit if a trend is established. A low BMI secondary to 
malnutrition is common in patients with undiagnosed IBD or those 
who are relapsing. These patients could therefore benefit from an 
escalation of their treatment [11]. 
As discussed, a pre-biologic screen ensures patient safety when 
considering initiating a biologic treatment. This screen encompasses 
multiple tests, including blood analysis and imaging. Patient letters 
infrequently (33%) mention that this has been completed. At ESHT 
there is no standardized format for the completion of these tests. As 
this is an important reoccurring routine step of treating a patient with 
a biologic, this would lend itself well to a checklist. This could assure 
all healthcare professionals involved in the biologic management that 
a biologic screen has been done. It would also potentially prevent 
duplicate testing if accurately documented. A completed checklist 
would be suitable for repeated audits to ensure compliance. 
Having clearly defined and documented parameters for treatment 
cessation is important to the next clinician assessing this patient. 
Treatment should not be long-term as this predisposes to an 
increased incidence of serious infections and risk of non-melanoma 
skin cancer [18]. Once a patient is initiated on adalimumab, a 
conversation about treatment duration should be considered. 
Anecdotally, unclear endpoints concerning treatment duration both 
increase the risk of patients being reluctant to cease treatment and 
increase the duration of treatment. In addition, this manages patient 
expectations who may not realize that the focus of the treatment is 
to induce remission as opposed to a lifelong strategy. Prolonged 
treatment would also add financial pressure on the healthcare 
system, not only with adalimumab being a high-cost drug but also in 
the form of additional clinic appointments. Lastly, as different 
clinicians may be reviewing this patient over time, a defined 
endpoint would improve continuity of care. 
This data suggests that important parameters are not routinely 
recorded in patient letters where they are easily accessible. 
Improving documentation in these identified parameters can 
improve patient care through improved communication. This results 
in better continuity of care and allows the healthcare team to 
establish relevant trends. 
The results indicated that follow-up of patients after they have been 
started on a biologic shows inconsistency. The optimal time frame 
for follow-up in patients that are on biologic treatment should occur 
within 2-3 mo followed by an annual review [11]. These parameters 
were adhered to in only 43% of cases at the 3-month and 26% at the 
annual review. These reviews ensure that patients receive the 
maximum benefit from the treatment, assess side effects, and review 
the indication of the medication. A large majority (73%) of patients 
are booked into additional clinics throughout the year. Even though 
patients were being booked into additional clinics, it was still 
deemed necessary to reassess the patient care 77% of the time after 
an MDT meeting between a Consultant Gastroenterologist and an SP. 
Reviewing patients at 3-month intervals could be a factor using up 
resources and time. By reducing the number of appointments and 
scheduling reviews annually, clinicians and healthcare staff could 
use their time more efficiently. As highlighted by the NICE guidelines 
above, the management of patients who have IBD requires multiple 
assessments repeatedly occurring over time to ensure optimal 
management. An IBD SP would be able to be involved in the anti-
TNF-a drug protocol used in IBD. This could include pre-screening, 
initiating treatment, monitoring, and ongoing treatment 
requirements. 
A limitation encountered in this study was that some patients had 
been on adalimumab before the introduction of the Blueteq® 
database in January 2016. Although these patients were identified, 
this limited data collection for some parameters and could 
contribute towards Non-Available (NA) data. Furthermore, following 
the introduction of Blueteq®, the existing patients were seen as 
legacy patients and therefore continued on treatment regardless of 
NICE guidelines. During this study, significant amounts of the data 
were extracted from clinic letters, which are primarily written to 
communicate with the patient and their primary healthcare 
provider. Therefore, important information not relevant to these 
parties could have been excluded. Clinicians and allied healthcare 
staff did document separately on written records, however, there 
was no access to these archived notes. Lastly, due to limitations in 
funding and time, it was not possible to assess the impact an SP 
could make on IBD biologic management.  
SPs have been noted to make a significant difference in other 
treatments. Mikolas et al., described the deployment of an SP in a 
Hepatitis C Virus treatment clinic [4]. The SP treated patients with 
direct-acting antivirals. Their tasks included pre-treatment 
screening, drug selection, therapeutic drug monitoring, adherence, 
and follow-up. The sustained virologic response of the patients 
treated under a clinical pharmacist specialist using direct-acting 
antivirals was similar to previous literature [4]. SPs were also 
J. Hegner et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 11, 30-33 
33 
investigated by Walter et al., who evaluated whether the complex 
medication for lung cancer patients could be managed by SP [3]. 
Evaluated over 6 mo, medication adherence and patient satisfaction 
improved significantly. The healthcare system benefited from a 
significant reduction in-clinic appointments. One study investigated 
the impact a pharmacist could have on outpatients receiving 
haemodialysis. The authors identified this group as high-risk for 
drug-related problems due to multiple co-morbidities and 
polypharmacy. The study found that having a pharmacist review 
patient's medications reduced ineffective and suboptimal drug 
therapy [19].  
A study conducted by Brighton and Sussex University Hospitals 
(BSUH) trust, imbedded an SP into the multi-disciplinary team [20]. 
The SP provided an independent prescribing, TDM, and biologic 
infusion clinic service. Analysis following this implementation found 
significant cost savings, decreased clinic slots for the gastroenterology 
doctors and nurse specialists, and enhanced patient safety through 
improved TDM and standardization in patient management. 
CONCLUSION 
Conditions that require complex care, a multi-disciplinary approach, 
regular TDM, and constant re-evaluation can benefit from the 
supervision of a dedicated SP. The data presented in this paper along 
with the supporting literature, makes for an argument that the IBD 
management at ESHT could greatly benefit from a dedicated SP. Our 
observations along with the publications by Mikolas et al., Walter et 
al., and the team at BSUH, support SP covering part of the patient 
care, doing this safely, and decreasing workload on other healthcare 
members. Our data illustrated that 73% of patients are booked into 
additional clinics, whilst a majority of patients are not assessed at 
the correct intervals. The Royal Pharmaceutical society recognizes 
the pharmacist’s role as an independent prescriber and states that 
this will help “drive quality improvement in the delivery of care”. 
Pharmacist independent prescribers will “lead to more effective 
models of care for” all of our patients [5]. To strengthen the claim 
that SP adds significant value, a cohort study investigating the 
impact of an SP on patient care of adalimumab for IBD at ESHT 
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